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Background: Smoking is seen as the most important single risk to health today, and is responsible for a high
financial burden on healthcare systems and society. This population-based cross-sectional study compares
healthcare utilisation, direct medical costs, and costs of productivity losses for different smoking groups: current
smokers, former smokers, and never smokers.
Methods: Using a bottom-up approach, data were taken from the German KORA F4 study (2006/2008) on self-
reported healthcare utilisation and work absence due to illness for 3,071 adults aged 32-81 years. Unit costs from a
societal perspective were applied to utilisation. Utilisation and resulting costs were compared across different
smoking groups using generalised linear models to adjust for age, sex, education, alcohol consumption and
physical activity.
Results: Average annual total costs per survey participant were estimated as €3,844 [95% confidence interval: 3,447-
4,233], and differed considerably between smoking groups with never smokers showing €3,237 [2,802-3,735] and
former smokers causing €4,398 [3,796-5,058]. There was a positive effect of current and former smoking on the
utilisation of healthcare services and on direct and indirect costs. Total annual costs were more than 20% higher
(p<0.05) for current smokers and 35% higher (p<0.01) for former smokers compared with never smokers, which
corresponds to annual excess costs of €743 and €1,108 per current and former smoker, respectively.
Conclusions: Results indicate that excess costs for current and former smokers impose a large burden on society,
and that previous top-down cost approaches produced lower estimates for the costs of care for smoking-related
diseases. Efforts must be focused on prevention of smoking to achieve sustainable containment on behalf of the
public interest.
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Worldwide, tobacco smoking is seen as the most urgent
health risk behaviour requiring prevention today [1].
The list of diseases caused by smoking includes cancer,
cardiovascular diseases, respiratory illnesses and many
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reproduction in any medium, provided the orquality of life [3,4] and is responsible for more than five
million deaths worldwide every year [5]. Mortality and
morbidity associated with smoking have considerable fi-
nancial consequences for healthcare systems and econ-
omies [6,7]. In Germany, smoking is still prevalent despite
a reduction in recent years: 30% of the population aged 18
and older are smokers, 26% former smokers, while 44%
have never smoked [8]. Previous studies have shown that
smoking results in higher utilisation of medical services
[9,10], augmented work absenteeism [11-13] and in-
creased resulting costs [14,15]. Despite their shortened lifeLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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costs [17-19].
Several studies have explored the financial burden of
smoking in Germany [20-26], reporting total smoking-
attributable costs from €17.4 billion to €33.6 billion for
different base years, with productivity losses accounting
for as much as between 72-74% of total costs [20,22].
However, these previous German studies all used a top-
down approach. As this approach uses the concept of
smoking-attributable fractions for mortality and morbid-
ity known to be caused by smoking, the estimated finan-
cial burden of smoking may be inadequate if diseases and
risks used for attribution do not fully reflect the structure
of current smoking impact in Germany. For example,
these studies used attributable mortality risks for attribut-
ing morbidity due to data limitations. Mortality risks may
differ from morbidity risks and from the utilisation risk in
the population at the time of sampling. Alternatively, the
actual economic impact of smoking can be calculated by
estimating excess costs of smokers compared to never
smokers in a data set comprising current utilisation of in-
dividuals. This approach has the advantage of considering
the entire spectrum of disease consequences associated
with smoking and confounding factors [27].
The objective of this study was to assess differences in
the utilisation of medical services and in direct and indirect
costs from a societal perspective among current, occasional,
former and never smokers using a population-based sam-
ple. To our knowledge, this is the first study in Germany
to apply a bottom-up approach to estimate excess costs of
smoking.
Methods
Data and study design
We used data from the KORA (Cooperative Health Re-
search in the Augsburg Region) F4 survey, a population-
based study conducted in 2006-2008 in Southern Germany.
The F4 study is the follow-up of the KORA S4 survey
(1999-2001). In brief, KORA S4 randomly selected 6,640
adults of German nationality aged 25-74 in the city of
Augsburg and the two adjacent administrative districts
from population registries; of those, 4,261 participated in
the baseline examination. Details about design, sampling
xmethod, data collection and response rates have been de-
scribed elsewhere [28,29]. 3,080 individuals from S4 (72%)
also participated in the follow-up survey F4, in which self-
reported information on current smoking status, healthcare
utilisation and non-productive working time was assessed
in standardized computer-assisted interviews.
Participants were classified as current smokers if they
smoked at least one cigarette per day at the time of the
interview, as occasional smokers if they smoked usually
less than one cigarette per day, as former smokers if they
had smoked regularly or occasionally in the past and asnever smokers if they had never smoked or less than 100
cigarettes in their lifetime.
Smoking status in F4 was compared with previous S4
information, and nine participants were excluded due to
missing or implausible information on smoking status.
Thus, the final study sample for this cross-sectional F4
analysis contained 3,071 subjects.
Information on age, sex, education (basic (≤9 years),
secondary (10-11 years), higher (≥12 years)), alcohol
consumption (based on WHO proceedings [30]: low risk
alcohol consumption (average daily alcohol intake ≤ 20 g
for women and ≤ 40 g for men), risky alcohol consump-
tion (daily intake > 20 g for women and > 40 g for men))
and physical activity (active (regular sports in leisure
time in summer and winter time for ≥ 1 hour per week),
inactive (< 1 hour of sports per week)) were assessed in
addition in F4.
A subsample of former smokers gave additional infor-
mation on the date (n=1,164) and on reasons (n=791) for
quitting in an additionally administered questionnaire.Assessment of healthcare utilisation and cost components
Utilisation of medical services
As described previously, participants were asked to state
the number of times they had visited a physician in the
previous 3 months, subdivided for 15 ambulatory speciali-
sations [31]. Additionally, the numbers of ambulatory hos-
pital visits, visits to alternative physicians and physical
therapy treatments in the previous 12 months were
recorded, as were the numbers of inpatient hospital days
(including days in intensive care units), and inpatient and
outpatient rehabilitations. Finally, use of pharmaceuticals
in the previous week was assessed, detailing name, na-
tional drug code, dosage, interval of intake, and prescrip-
tion status.Direct costs
For monetary valuation of health services, national unit
costs were applied as recommended by the Working
Group Methods in Health Economic Evaluation (AG
MEG) [32]. These unit costs were updated to the year
2008 (Additional file 1: Table S1).
Costs per physician contact for each medical specialty
and per physical therapy unit were updated from 1999
to 2008 using the rate of change in physician reimburse-
ment per case [33]. The resulting contact values for
physician visits vary from €18.3 for psychiatrists to €99.6
for radiologists, and are €26.1 for physical therapy. The
number of physician contacts and physical therapies was
multiplied with the corresponding contact value to de-
termine costs. If participants stated that they had visited
a physician in the previous 3 months but did not indi-
cate the number of visits (n=7), one visit was assumed
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lysis, the mean number of visits was imputed instead.
Costs for alternative physicians were requested
directly. If participants stated that they had visited an
alternative physician but did not specify their costs
(n=45), the average costs per visit stated by the users
was imputed (€50).
As the reason for hospitalisation was unavailable, hos-
pital days and days spent in the intensive care unit were
valued using mean costs per day as suggested by the AG
MEG. Unit costs were updated from 2000 to 2008 as de-
scribed by the AG MEG and using data from the Federal
Statistical Office [32,34,35], yielding costs of €451 per hos-
pital day and €1,293 per day in the intensive care unit.
Costs per ambulatory hospital treatment were assessed as
one physician visit according to social legislation. Based
on data on average costs and length of ambulatory and
stationary rehabilitation from the German Pension Fund
[36], costs per inpatient and outpatient rehabilitation were
estimated as €100 and €62 per day, respectively.
Utilisation of pharmacy only pharmaceuticals was
estimated using participant’s information about name,
national drug code and dosage of intake within the
previous week, and costs were calculated from 2008
pharmacy retail prices [37] by subtracting mandatory
discounts of manufacturers and pharmacies according to
the Social Security Code for statutory health insurance.
Non-pharmacy medicines, dietary supplements and vita-
mins were excluded.
Total annual direct medical costs were calculated by
extrapolating physician and drug costs to 12 months,
and summing the costs of all health services.
Indirect costs
To assess indirect costs with regard to production losses
in those aged 65 years or younger, participants were
asked whether disability benefits were obtained, and
those with regular employment were asked how many
days they had been absent from work due to illness in
the previous 12 months. If participants stated a greater
number of days of absence from work than the max-
imum number of 213 working days in 2008 in Germany,
their days of absenteeism were restricted to 213 (n=6).
Following current guidelines, we used the human capital
approach to calculate productivity losses in paid work for
society [38]. As methodological discussion about the most
appropriate approach is still on-going, we additionally ap-
plied the frictional costs approach within a sensitivity ana-
lysis [39]. Whereas the human capital approach assumes a
perfect labour market, the frictional costs approach
charges only 80% of losses of the human capital approach
to avoid potential overestimation of indirect costs [32].
Annual labour costs published by the Federal Statis-
tical Office [40] were used to value productivity lossesper year of disability in accordance with AG MEG
guidelines. Costs per day of work lost were calculated
by dividing annual labour costs by 213 working days in
2008, yielding costs of €160 per working day. Costs due
to unpaid work, further premature retirement and
death, as well as intangible cost resulting out of pain or
decrease in quality of life, were not considered.Statistical analysis
Unadjusted analyses were performed regarding partici-
pants’ smoking status, healthcare utilisation and costs.
To account for non-normality of cost data, 95% confi-
dence intervals (CI) were estimated via a non-parametric
bootstrap approach using a percentile method based on
1,000 replications.
The effect of smoking status on healthcare utilisation
and work absenteeism was analysed in a two-step hur-
dle approach: In a first step we used multiple logistic
regression models to calculate odds ratios of healthcare
utilisation or inability to work as a function of smoking
status, age, sex, education, alcohol consumption and
physical activity. Secondly, for users only, factors in-
fluencing the number of healthcare service uses were
analysed with generalised linear models assuming a
zero-truncated negative binomial distribution with a
log-link.
Finally, the effect of smoking status on direct, indirect
and total healthcare costs was analysed, again adjusting
for age, sex, education, alcohol consumption and physical
activity. To consider the typically skewed distribution of
costs, generalised linear models were used assuming a
gamma distribution with log-link, where costs of €1 were
assigned to participants with zero costs. This approach
has been demonstrated to be a suitable method for
healthcare costs [41,42].
Appropriate tests were operated to confirm the choice
of distribution and link function. Regarding total costs, the
Modified Park Test supported the choice of the gamma
distribution (p=0.39), and the Hosmer-Lemeshow-Test
(p=0.61), the Pregibon Link-Test (p=0.63) as well as the
Pearson Correlation Test (p=0.90) all confirmed the
choice of the log link function.
Due to missing data on three participants for education,
the regression analysis contained 3,068 observations.
Statistical analyses were performed using SAS soft-
ware (SAS Institute Inc., Cary, NC, USA, Version 9.2),
and p-values of 0.05 or less were considered to be statis-
tically significant.
Non-linear relationships of variables were checked as
well as possible interactions by using variable selection
methods (PROC GLMSELECT with stepwise selection
method), but no significant non-linear relationships and
interactions were observed.
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Unadjusted analyses
Table 1 gives the socio-demographic characteristics of the
study sample. Of all participants, 15% were current
smokers, 3% occasional smokers, 41% former smokers and
42% never smokers. Groups differ significantly regarding
sex (p<0.0001), age (p<0.0001), and consequently in alco-
hol consumption (p<0.0001) and physical activity (p<0.01).
The proportion of users and the mean frequency of
utilisation for each healthcare service are given in the
Additional file 1: Table S1. Table S2 in the Additional
file 1 shows average annual direct medical, indirect and
total costs per smoking group. Eleven per cent of partic-
ipants had zero total costs, 14% had no direct medical
costs and 60% no indirect costs.
Overall, mean total annual costs per survey participant
were €3,844 (95% CI: 3,847-4,233); €1,645 of these were
indirect costs (43%), subdivided between costs of tem-
porary absenteeism (43%) and disability benefits (57%).
The largest shares of direct medical costs were due to
hospital treatment (43%), pharmaceuticals (29%) and
physician visits (15%).
Total costs ranked highest for former smokers at €4,398,
followed by current smokers (€4,159), never smokers
(€3,237) and occasional smokers (€3,074).
Regression analysis
Table 2 reports the effect of smoking status on the prob-
ability of using healthcare services, being absent from
work or receiving disability benefits. Current smokers
showed significantly lower odds ratios for physician









Sex Women 210 (44.9%) 41 (51.
Men 258 (55.1%) 38 (48.
Age 49.68 (10.5) 48.84 (
Educationa Basic education 237 (50.6%) 37 (47.
Secondary education 134 (28.6%) 22 (28.
Higher education 97 (20.7%) 19 (24.
Alcohol
consumption
low risk (women: ≤20 g,
men: ≤40 g alcohol per day)
382(81.6%) 69 (87.
elevated risk (women: >20 g,
men: >40 g alcohol per day)
86 (18.4%) 10 (12.
Physical activity active 228 (48.7%) 51 (64.
inactive 240 (51.3%) 28 (35.
Data are presented as n (%)/mean (standard deviation). Any discrepancies in percen
an=3 participants with missing information on school education. These subjects we
bp-value based on Chi2-test.
cp-value based on ANOVA.smokers. By contrast, former smokers showed significantly
higher odds for hospital treatment, for rehabilitation and
for pharmaceutical intake compared to never smokers.
The effect of smoking status on the number of medical
services used and of working days absent is summarised
in Table 3. Among users of physician treatments, current
and former smokers showed higher numbers of visits
than never smokers. Furthermore, former smokers used
a greater amount of pharmaceuticals. Among participants
who had been absent from work, the number of days
absent from work was significantly higher in smokers.
In all, smokers had a lower probability of physician
treatments, but those utilising physician treatments
showed an increased number of treatments compared
with never smokers. Similarly, smokers showed a lower
probability of being absent from work, but if they were
absent the duration was 44% higher than in never
smokers. In former smokers, both the probability of using
pharmaceuticals and the number of pharmaceuticals used
were greater compared to never smokers.
Table 4 shows the regression results for costs. Compared
with never smokers, former smokers showed a 26% in-
crease in direct medical costs (p=0.001) and 31% increase
in indirect costs (p=0.03). Current and former smokers
had 24% and 35% higher total annual costs (p=0.026 and
p=0.001), respectively, than never smokers, corresponding
to excess costs of €744 per current and €1,108 per former
smoker.
Additionally, age was associated with both higher dir-
ect and indirect costs, and men had higher indirect costs
but lower direct medical costs than women. Participants














9%) 517 (41.5%) 824 (64.5%) 1592 (51.8%) <0.0001 b
1%) 729 (58.5%) 454 (33.5%) 1479 (48.2%)
12.2) 57.40 (13.2) 57.49 (13.5) 56.04 (13.3) <0.0001 c
4%) 648 (52.1%) 661 (51.8%) 1583 (51.6%) 0.32 b
2%) 301 (24.2%) 300 (23.5%) 757 (24.7%)
4%) 296 (23.8%) 316 (24.8%) 728 (23.7%)
3%) 1031 (82.7%) 1160 (90.8%) 2642 (86.0%) <0.0001 b
7%) 215 (17.3%) 118 (9.2%) 429 (14.0%)
4%) 699 (56.1%) 693 (54.2%) 1671 (54.4%) 0.01 b
4%) 547 (43.9%) 585 (45.8%) 1400 (45.6%)
tages are due to rounding.
re excluded from the regression analysis.
Table 2 Probability of using medical services – results of logistic regression models – adjusted for age, sex, school
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1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00
n=3068 due to missing information on school education in three subjects.
*** significant at the 1% level/** significant at the 5% level/* trend with p≤0.10.
an=3,067: four observations with missing information on physical therapy.
bn=1,499: work absence only for persons with information on occupational status and age ≤65.
cn=2,176: 22 observations with missing information on disability benefits.
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medical costs. Participants who stated no regular phys-
ical activity showed higher direct costs than active
participants. Detailed regression results can be found in
the Additional file 1: Table S3.
Analysis of a subsample of former smokers showed that
participants who quitted smoking in the last 12 months
caused 2.37 (p<0.0005) times higher total costs than
former smokers who quitted more than 12 months ago.
Further subsample analysis in 791 former smokers showed
that participants who quitted because of medical condi-
tions caused significantly higher costs (92%) than former
smoking participants who did not quit because of this rea-
son. Former smokers who quitted in order to prevent fu-
ture diseases showed only 63% of costs of participants for
whom prevention was not an issue. Other reasons like fi-
nancial aspects, pregnancy or fear of lung cancer had no
significant influence on total costs in this subsample.Table 3 Frequencies of utilisation (users-only) – results of zer










































*** significant at the 1% level/** significant at the 5% level/* trend with p≤0.10.Sensitivity analysis
Imputing the mean frequency of physician visits instead
of one for the seven participants with missing frequen-
cies did not affect results. Application of the frictional
cost approach decreased indirect costs by 20% and total
costs by 9%, but differences between smoking groups
remained unchanged. Also, varying the amount of costs
attributed to participants with zero costs in the regres-
sion analysis from €1 to €0.5 or €5 affected neither the
coefficients nor their significance.
Discussion
This study investigated the effect of smoking status on
healthcare utilisation and direct and indirect costs in a
population-based sample.
Total annual costs for current and former smokers
were 24% and 35% higher, respectively, than for never
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exp(estimate) exp(estimate) exp(estimate) exp(estimate)

























1.00 1.00 1.00 1.00
Table 4 Annual direct medical, indirect and total costs – results of the Gamma regression models – adjusted for age,
sex, school education, alcohol consumption and physical activity
Parameter Total direct medical costs Total indirect costs Total costs
exp(estimate) exp(estimate) exp(estimate)
[95% CI] [95% CI] [95% CI]
Smoking status Current smoker 1.06 [0.88–1.27] 1.28 [0.95–1.73] 1.24 ** [1.03 – 1.49]
Occasional smoker 0.73 [0.50–1.06] 1.26 [0.68–2.36] 0.96 [0.65 – 1.41]
Former smoker 1.26 *** [1.10–1.45] 1.31 ** [1.03–1.68] 1.35 *** [1.18 – 1.55]
Never smoker 1.00 1.00 1.00
*** significant at the 1% level/** significant at the 5% level.
n=3,068 due to missing information on school education in three subjects.
1€ was assigned to observations with costs=0.
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smoker. This was the first study to analyse costs of
smoking in Germany using a bottom-up approach.
In all, our findings are in line with other international
studies that have shown increased healthcare utilisation
and costs in current and former smokers [6,9,12,14,15,43].
Similar to a health survey from the US [9], we found an
increased risk of inpatient visits and an increased number
of physician visits in former smokers. Our findings that
current smokers showed a lower probability of physician
treatments compared to never smokers, but a higher num-
ber of treatments if they used physician treatments at least
once, is comparable to a recent study which found a de-
creased likelihood of current smokers to use primary care
services but slightly increased costs [44]. This pattern
could be explained by the possibility of a healthy smoker
effect or special attitudes of smokers which translate into
denial of disease and delays in seeking healthcare [44].
Regarding cost, our results suggest that former
smokers incur even higher costs than current smokers.
Within the subsample of former smokers, we observed
that those who had quit smoking in the previous 12
months caused considerably higher total costs than
those who had quit more than 12 months previously
(factor 2.37, p=0.0005). Other studies also have found
that former smokers induce higher medical costs within
a period after cessation or shortly before quitting
[9,14,45]. This may be explained by arising health prob-
lems being the reason for smoking cessation. Neverthe-
less, subsample analysis showed that even former
smokers who had quit more than 10 years ago cause
higher total annual costs than current smokers (28% vs.
23% higher total costs compared to never smokers,
p=0.002).
Further analysis showed that subjects who quit smok-
ing due to existing medical conditions had higher total
costs irrespective of their period of non-smoking. We
also found that former smokers who quit in order to
prevent future diseases showed substantially lower total
costs, which could be explained by overall more health-
conscious behaviour.Up to now, only a few studies have examined the eco-
nomic burden of cigarette smoking in Germany [20-23].
Using a top-down approach, these studies identified
direct and indirect costs attributable to smoking of €17.4
billion for the year 1993 [22] and €21 billion for the year
2003 [21]. As this approach uses the concept of smoking-
attributable fractions for mortality and morbidity known
to be caused by smoking, health conditions where smok-
ing may be one of several contribution factors are
neglected. Furthermore these previous top-down studies
used attributable mortality risks for attributing morbidity.
Mortality risks may differ from morbidity risks and from
healthcare utilizations probabilities. In addition, in focus-
sing on mortality risks this method solely considers
smoking-related fatal diseases and neglects non-fatal
health consequences of smoking like e.g. osteoporosis or
eye diseases like cataract and glaucoma. Therefore this
approach is known to downward-bias cost estimates [27].
Compared to top-down approaches, calculating excess
costs based on subject-level data has the advantage of
considering the entire spectrum of disease consequences
associated with smoking. In addition, the bottom-up
methodology used in this study provides better adjust-
ment for the actual impact of smoking on health condi-
tions and for population characteristics as it considers
other differences in smokers and non-smokers regarding
education and other risky behaviours besides smoking.
Disregarding issues of representativeness, the results of
our study can be extrapolated to the whole population of
Germany using data on national smoking prevalence [8].
Excluding costs of premature deaths, which were not mea-
sured in this study, smoking caused costs of €31.3 billion in
2008. Direct costs amounted to €17.9 as opposed to €8.23
billion in the top-down approach (inflated from €7.48 bil-
lion in 2003 using the consumer price index (CPI)) [21].
However, our results can only be based on the prevalence
of smoking in a study population aged 32-81 years, which
is lower than the national average used for projection. Tak-
ing these limitations into account, results strongly indicate
that cost-of-illness estimates at the population level by the
top-down approaches have been too conservative.
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study, direct costs per current smoker derived from our
bottom-up study exceed those of the top-down approach
of €381 (inflated from €346 in 2003 using the CPI) [21]
by nearly a factor of 2. This can be explained by the fact
that top-down studies solely consider costs of diseases
which are known to be associated with smoking or by
different populations under study. Furthermore, using the
bottom-up approach, costs for former smokers exceed
those for current smokers by more than 45%. In contrast,
using the top-down approach, costs for former smokers
are smaller than those for current smokers, because all
relative risks of smoking-related diseases for former
smokers are smaller than those for current smokers. As
former smokers in the cross-sectional KORA sample are
about 8 years older than current smokers, they incur a
higher probability of suffering from smoking-related dis-
ease with a delayed onset whereas health damage resulting
of smoking may not yet have been revealed in current
smokers.
A methodological issue, top-down studies base their
calculation of excess cost on the entire adult population.
In this bottom-up approach, the KORA population sam-
ple does not comprise younger age groups and might thus
incur higher excess costs on average. As top-down studies
do not consider age in the calculation of attributable
healthcare utilisation and costs, an age-standardized com-
parison is beyond the scope of this paper. Differences in
underlying age distribution are a restriction to this com-
parison of excess costs.
There are several limitations to our study. First, the
cross-sectional design is susceptible to recall bias, as
participants were asked to provide information retro-
spectively. By applying a recall time horizon of 1 week
for pharmaceuticals, 3 months for physician visits and
12 months for more memorable services, the study de-
sign attempted to minimise this problem. This approach
has been shown to be valid [46]. Nevertheless, recall
error may have occurred, but it is unlikely to have
affected the validity of our results because this may not
have influenced the differences between the smoking
groups [47].
Furthermore, as smoking habits were assessed by self-
report without validation via biochemical tests, partici-
pants may have given socially desirable answers which are
also prone to recall bias regarding smoking behaviour in
the past. Therefore, the number of smokers may be
underestimated, but any bias was minimised by comparing
current information on smoking status with information
from the previous survey.
Also, despite high recruitment efforts which positively
affects representativeness [48], we cannot exclude selec-
tion bias. Whereas 75% of occasional, former and never
smokers of the previous S4 survey were followed-up inthe F4 survey, current smokers were underrepresented
with a follow-up rate of 65%. This could be caused by
higher death rates of current smokers or other unob-
served factors, which could lead to systematic under- or
overestimation of costs.
Monetary valuation of health services requires several
assumptions that may cause under- or overestimation of
costs. Also, unit costs were inflated to the year 2008. As
the German healthcare sector has undergone considerable
changes due to policy and law, real costs may have
changed differently. Nevertheless, our updating approach
represents a pragmatic approximation, and, although this
may influence the amount of costs, differences between
the smoking groups are unlikely to be affected.
Moreover, by using mean costs, differences in treatment
intensity are not considered. Hospital costs in particular
can differ significantly depending on the specialty depart-
ment [32].
Drug costs were estimated based on participants’ in-
formation on intake and dosage. Using the defined daily
dose methodology, as suggested by the WHO [49], leads
to 5.4% higher costs with differences between smoking
groups, but their ranking remains unchanged. As this
approach assumes full compliance of patients, it was
not considered.
Additional components of medical services such as
nursing, medical aids and appliances and other medical
therapies like logopaedia could not be included. How-
ever, the components considered in our study covered
about 75% of total healthcare costs in 2008 [50]. Fur-
thermore, direct non-medical costs, such as time and
travel expenses, costs of premature death and intangible
costs could not be considered. Although this probably
led to underestimation of total costs for society, it is
unclear if relative differences between smoking groups
were affected.
Moreover, we cannot exclude confounding through
differences in unobserved behaviours. The effect of
smoking could, therefore, be under- or overestimated,
for example by not adjusting for other risk behaviour
patterns or socio-demographic characteristics, which
could differ systematically between the smoking groups.
In order to minimize potential confounding we con-
trolled for alcohol consumption and physical activity.
The inclusion of these factors hardly influenced the
results concerning smoking status. Nevertheless, the
levels of physical activity and alcohol consumption
could also be the result of underlying health conditions
which cannot be analysed in cross-sectional data. E.g. the
finding that high risk alcohol consumption is associated
with lower direct medical costs has to be explored in detail
elsewhere.
Finally, the cross-sectional design of the KORA study
gives a snapshot of medical utilisation and its costs, but
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proach and therefore any accounting for the possibility
of shorter life expectancy of smokers. Several studies
have shown that lifetime medical costs of current and
former smokers are increased compared with never
smokers and outweigh potential cost savings due to
shorter life expectancy [17-19].
Conclusions
In conclusion, our results emphasise that smoking incurs
high direct and indirect costs, and therefore imposes a
significant burden on society. The economic impact of
this public health problem highlights the importance of
efforts aiming to discourage smoking. Although further
research is needed to examine dose-effect relations of
smoking, the timing of quitting on societal costs and re-
sults from longitudinal studies, policy makers should
strengthen their efforts towards prevention, for example
in realising the WHO Framework Convention on Tobacco
Control [51] which suggests measures to reduce tobacco
demand and therefore prevents smoking and its negative
economic consequences.
Additional file
Additional file 1: Table S1. Utilisation of healthcare services and unit
costs. Table S2. Unadjusted mean annual direct medical and indirect
costs by smoking status. Table S3. Detailed results of regression analyses.
Competing interests
The authors declare no competing interests. The sponsors were not involved
in the study design, collection, analysis and interpretation of data; in the
writing of the manuscript; and in the decision to submit the manuscript.
Authors’ contributions
MW conceptualised the paper, performed the statistical analysis, interpreted
the data and drafted the manuscript. RH was involved in the coordination of
the study and commented on drafts of the paper. RL commented on drafts
of the paper. AP, JH and KHL were involved in the coordination of the study.
PM supported conception, gave statistical support and assisted in writing the
manuscript. All authors read and approved the final manuscript.
Acknowledgements
The KORA research platform (KORA, Cooperative Research in the Region of
Augsburg) was initiated and financed by the Helmholtz Zentrum München –
German Research Center for Environmental Health (GmbH), which is funded
by the German Federal Ministry of Education and Research and by the State
of Bavaria. The Helmholtz Zentrum München is Member of the German
Center for Lung Research.
Funding
This work was supported by the “Kompetenznetz Asthma/COPD
(Competence Network Asthma/COPD)” funded by the Federal Ministry of
Education and Research (FKZ 01GI0881-0888).
Author details
1Helmholtz Zentrum München - German Research Center for Environmental
Health (GmbH), Institute of Health Economics and Health Care Management,
Member of the German Center for Lung Research, Comprehensive
Pneumology Center Munich (CPC-M), Ingolstaedter Landstr. 1, Neuherberg
85764, Germany. 2Helmholtz Zentrum München - German Research Center
for Environmental Health (GmbH), Institute of Epidemiology I, Member of theGerman Center for Lung Research, Comprehensive Pneumology Center
Munich (CPC-M), Ingolstaedter Landstr. 1, Neuherberg 85764, Germany.
3Helmholtz Zentrum München - German Research Center for Environmental
Health (GmbH), Institute of Epidemiology II, Member of the German Center
for Cardiovascular Research, Ingolstaedter Landstr. 1, Neuherberg 85764,
Germany. 4Ludwig-Maximilians-Universität München, Institute of Health
Economics and Health Care Management, Ludwigstr. 28 RG, Munich 80539,
Germany.
Received: 5 September 2012 Accepted: 15 July 2013
Published: 17 July 2013
References
1. Beaglehole R, Bonita R, Horton R, Adams C, Alleyne G, Asaria P, Baugh V,
Bekedam H, Billo N, Casswell S, et al: Priority actions for the non-
communicable disease crisis. Lancet 2011, 377(9775):1438–1447.
2. U.S. Department of Health and Human Services: The Health Consequences of
Smoking: A Report of the Surgeon General. Atlanta: U.S. Department of Health
and Human Services, Centers for Disease Control and Prevention, National
Center for Chronic Disease Prevention and Health Promotion, Office on
Smoking and Health; 2004.
3. Jia H, Lubetkin EI: Trends in quality-adjusted life-years lost contributed by
smoking and obesity. Am J Prevent Med 2010, 38(2):138–144.
4. Vogl M, Wenig C, Leidl R, Pokhrel S: Smoking and health-related quality of
life in English general population: implications for economic evaluations.
BMC Public Health 2012, 12(1):203.
5. World Health Organization: WHO report on the global tobacco epidemic,
2009: Implementing smoke-free environments. Geneva: World Health
Organization; 2009.
6. Max W: The financial impact of smoking on health-related costs: a review
of the literature. Am J Health Promot 2001, 15(5):321–331.
7. Bank W: Curbing the Epidemic: Governments and the Economics of Tobacco
Control. Washington: The World Bank; 1999.
8. Lampert T: Smoking - recent trends in adults. In GBE kompakt 2 (4) -
Zahlen und Trends aus der Gesundheitsberichterstattung des Bundes. Berlin:
Robert Koch-Institut; 2011.
9. Kahende JW, Adhikari B, Maurice E, Rock V, Malarcher A: Disparities in
health care utilization by smoking status - NHANES 1999-2004.
Int J Environmen Res Public Health 2009, 6(3):1095–1106.
10. Wagner EH, Curry SJ, Grothaus L, Saunders KW, McBride CM: The impact of
smoking and quitting on health care use. Arch Int Med 1995, 155(16):1789–1795.
11. Lundborg P: Does smoking increase sick leave? Evidence using register
data on Swedish workers. Tobacco Control 2007, 16(2):114–118.
12. Robbins AS, Fonseca VP, Chao SY, Coil GA, Bell NS, Amoroso PJ: Short term
effects of cigarette smoking on hospitalisation and associated lost
workdays in a young healthy population. Tobacco Control 2000,
9(4):389–396.
13. Weng SF, Ali S, Leonardi-Bee J: Smoking and absence from work:
systematic review and meta-analysis of occupational studies. Addiction
2013, 108(2):307–319.
14. Fishman PA, Khan ZM, Thompson EE, Curry SJ: Health care costs among
smokers, former smokers, and never smokers in an HMO. Health Serv Res
2003, 38(2):733–749.
15. Kiiskinen U, Vartiainen E, Puska P, Pekurinen M: Smoking-related costs
among 25 to 59 year-old males in a 19-year individual follow-up.
Eur J Public Health 2002, 12(2):145–151.
16. Doll R, Peto R, Boreham J, Sutherland I: Mortality in relation to smoking:
50 years’ observations on male British doctors. BMJ 2004, 328(7455):1519.
17. Hodgson TA: Cigarette smoking and lifetime medical expenditures.
Milbank Quarterly 1992, 70(1):81–125.
18. Rasmussen SR, Prescott E, Sorensen TI, Sogaard J: The total lifetime costs of
smoking. Eur J Public Health 2004, 14(1):95–100.
19. Rasmussen SR, Prescott E, Sorensen TI, Sogaard J: The total lifetime health
cost savings of smoking cessation to society. Eur J Public Health 2005,
15(6):601–606.
20. Adams M, Effertz T: The cost of smoking for the healthcare system and
society in Germany. In Alkohol, Tobacco and Complications. Stuttgart:
Thieme Verlag; 2010:57–64.
21. Neubauer S, Welte R, Beiche A, Koenig HH, Buesch K, Leidl R: Mortality,
morbidity and costs attributable to smoking in Germany: update and a
10-year comparison. Tobacco Control 2006, 15(6):464–471.
Wacker et al. BMC Health Services Research 2013, 13:278 Page 9 of 9
http://www.biomedcentral.com/1472-6963/13/27822. Welte R, König H, Leidl R: The costs of health damage and productivity
losses attributable to cigarette smoking in Germany. Eur J Public Health
2000, 10(1):31–38.
23. Ruff LK, Volmer T, Nowak D, Meyer A: The economic impact of smoking in
Germany. Eur Respiratory J 2000, 16(3):385–390.
24. Prenzler A, Mittendorf T, von der Schulenburg JM: [Modelling of the costs
of productivity losses due to smoking in Germany for the year 2005].
Gesundheitswesen 2007, 69(11):635–643.
25. Wegner C, Gutsch A, Hessel F, Wasem J: Smoking-attributable productivity
loss in Germany - a partial sickness cost study based on the human
capital potential method. Gesundheitswesen 2004, 66(7):423–432.
26. Wegner C, Gutsch A, Hessel F, Wasem J: Economic productivity losses as a
result of smoking - an analysis under consideration of the friction cost
method. Gesundh ökon Qual manag 2005, 10(6):356–364.
27. World Health Organization: Economics of Tobacco Toolkit - Assessment of the
Economic Costs of Smoking. Geneva: World Health Organization; 2011.
28. Holle R, Happich M, Lowel H, Wichmann HE: KORA–a research platform for
population based health research. Gesundheitswesen 2005,
67(Suppl 1):S19–S25.
29. Rathmann W, Haastert B, Icks A, Lowel H, Meisinger C, Holle R, Giani G: High
prevalence of undiagnosed diabetes mellitus in Southern Germany:
target populations for efficient screening. The KORA survey 2000.
Diabetologia 2003, 46(2):182–189.
30. World Health Organization: Comparative Quantification of Health Risks:
Global and Regional Burden of Disease Attributable to Selected Major Risk
Factors. Geneva: World Health Organization; 2004.
31. Menn P, Heinrich J, Huber RM, Jorres RA, John J, Karrasch S, Peters A, Schulz
H, Holle R: Direct medical costs of COPD - An excess cost approach
based on two population-based studies. Respir Med 2012, 106(4):540–548.
32. Krauth C, Hessel F, Hansmeier T, Wasem J, Seitz R, Schweikert B: Empirical
standard costs for health economic evaluation in Germany - a proposal
by the working group methods in health economic evaluation.
Gesundheitswesen 2005, 67(10):736–746.
33. National Association of Statutory Health Insurance Physicians. http://www.kbv.
de/2398.html.
34. Federal Statistical Office, [Hospital statistics on capacity utilisation]. https://
www.destatis.de/DE/Publikationen/Thematisch/Gesundheit/Krankenhaeuser/
GrunddatenKrankenhaeuser2120611117004.pdf?__blob=publicationFile.
35. Federal Statistical Office: Statistical Yearbook 2008 for the Federal Republic of
Germany. Wiesbaden: Federal Statistical Office; 2009.
36. German Pension Fund: Statistics on Rehabilitation in 2008. Berlin: German
Pension Fund; 2009.
37. Research Institute of the AOK. http://wido.de/arzneimittel.html.
38. Graf Von Der Schulenburg JM, Greiner W, Jost F, Klusen N, Kubin M, Leidl R,
Mittendorf T, Rebscher H, Schoeffski O, Vauth C, et al: German
recommendations on health economic evaluation: third and updated
version of the Hanover Consensus. Value Health 2008, 11(4):539–544.
39. Koopmanschap MA, Rutten FFH, van Ineveld BM, van Roijen L: The friction
cost method for measuring indirect costs of disease. J Health Econ 1995,
14(2):171–189.
40. Federal Statistical Office: National Accounts - Compensation per Employee,
Gross Wages and Salaries. Wiesbaden: Federal Statistical Office; 2011.
41. Barber J, Thompson S: Multiple regression of cost data: use of generalised
linear models. J Health Serv Res Policy 2004, 9(4):197–204.
42. Diehr P, Yanez D, Ash A, Hornbrook M, Lin DY: Methods for analyzing
health care utilization and costs. Ann Rev Public Health 1999, 20:125–144.
43. Izumi Y, Tsuji I, Ohkubo T, Kuwahara A, Nishino Y, Hisamichi S: Impact of
smoking habit on medical care use and its costs: a prospective
observation of National Health Insurance beneficiaries in Japan.
Int J Epidemiol 2001, 30(3):616–621.
44. Jorm L, Shepherd L, Rogers K, Blyth F: Smoking and use of primary care
services: findings from a population-based cohort study linked with
administrative claims data. BMC Health Servi Res 2012, 12(1):263.
45. Fishman PA, Thompson EE, Merikle E, Curry SJ: Changes in health care
costs before and after smoking cessation. Nicotine Tob Res 2006,
8(3):393–401.
46. Seidl H, Meisinger C, Wende R, Holle R: Empirical analysis shows reduced
cost data collection may be an efficient method in economic clinical
trials. BMC Health Serv Res 2012, 12(1):318.47. Evans C, Crawford B: Patient self-reports in pharmacoeconomic studies.
Their use and impact on study validity. Pharmacoeconomics 1999,
15(3):241–256.
48. Holle R, Hochadel M, Reitmeir P, Meisinger C, Wichmann HE: Prolonged
recruitment efforts in health surveys: effects on response, costs, and
potential bias. Epidemiol 2006, 17(6):639–643.
49. WHO Collaborating Centre for Drug Statistics Methodology: Guidelines for
ATC classification and DDD assignment 2010. Oslo: World Health
Organization; 2009.
50. Federal Ministry of Health: Statutory Health Insurance - Final accounting
results. 2008. http://www.bmg.bund.de/fileadmin/redaktion/pdf_statistiken/
krankenversicherung/kj-2008-endgueltige-rechnungsergebnisse.pdf.
51. World Health Organization: WHO Framework Convention on Tobacco Control.
Geneva: World Health Organization; 2003.
doi:10.1186/1472-6963-13-278
Cite this article as: Wacker et al.: The association of smoking status with
healthcare utilisation, productivity loss and resulting costs: results from
the population-based KORA F4 study. BMC Health Services Research
2013 13:278.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
